




## Supplemental Information

**Retrofusion of intraluminal MVB membranes parallels  
viral infection and coexists with exosome release**

**Priscillia Perrin, Lennert Janssen, Hans Janssen, Bram van den Broek, Lennard M. Voortman, Daphne van Elsland, Ilana Berlin, and Jacques Neefjes**




**A****B****C**

**Figure S1. Analysis of retrofusion measurement and TEV protease efficiency. Related to Figures 1 and 2.**

(A) Representative plot of intracellular median GFP fluorescence intensity from GFP-CD63 cells either (+) or not (-) cultured with dimerizer for the time indicated (min) N: nucleus; EL late endosomes as labelled by SiR-lysosome; Cyto: cytoplasm. EL: endolysosome; N: nucleus; PM: plasma membrane; Cyto: cytoplasm.

(B) Quantification of GFP-CD63 as detected by immunogold labeling on ILVs relative to LM (expressed as ratio per MVB) following incubation with dimerizer (6h). Shown is median +/- IQR from over 98 MVBs from 2 independent experiments.

(C) Analysis of Lamp1-TEV-TQ expression in GFP-CD63 retrofusion-monitoring cells stained with SiR-lysosome. Confocal fluorescence images of GFP-CD63 and Lamp1-TEV-TQ (white) distribution before (t=0h) and after (t=5h) treatment with dimerizer are shown, along with color overlays of GFP (green) or TQ (blue) with SiR-Lysosome (red). NLS-DsRED (magenta) in the nucleus indicate expression of the split TEV protease at t=0. Bar: 10  $\mu$ m. TQ : mTurquoise2.

**A****B****C**



**Figure S2. Effects of lipid and pH manipulation on the rate of ILV retrofusion. Related to Figure 3.**

(A) Confocal images of control (left panel; Ctrl) and U18666A treated (right panel) GFP-CD63 cells as used for monitoring retrofusion. Confocal fluorescence images of GFP-CD63 (*white*) distribution before (t=0h) and after (t=6h) treatment with dimerizer are shown, along with color overlays of GFP (*green*) with SiR-Lysosome (*red*). NLS-DsRED (*magenta*) in the nucleus indicate expression of the split TEV protease at t=0. All scale bars, 10  $\mu$ m.



(B) Representative plots of normalized median GFP fluorescence intensity in endolysosomes (as stained with SiR-lysosome) over time (min) following dimerizer addition in control cells (*gray*) versus those treated with Bafilomycin A, thioperamide or U18666A (*red*).

(C) Electron micrograph featuring immunogold labeling with GFP antibody of control cells following incubation with U18666A, thioperamide or Bafilomycin A. Scale bar, 200 nm.

A



C




**Figure S3. Effects of overexpression of the IFITM family members on the rate of ILV retrofusion. Related to Figure 4.**

(A) Confocal images showing overexpression of IFITM1 or 2 in GFP-CD63 retrofusion-monitoring cells, as used for the retrofusion experiments. Confocal fluorescence images of GFP-CD63 (*white*) distribution before (t=0h) and after (t=6h) treatment with dimerizer are shown, along with color overlays of GFP (*green*) with SiR-Lysosome (*red*). NLS-DsRED in the nucleus (*magenta*) and TQ-IFITM1 and 2 (*blue*) respectively indicate expression of the split TEV protease and the IFITM proteins at t=0. Scale bars, 10  $\mu$ m


(B) Localization of TQ-IFITM1, 2 and 3 proteins to late endocytic compartments as marked by SiR-Lysosome. Confocal fluorescence overlays of TQ-IFITM1-3 (*green*) with SiR-Lysosome (*red*) are shown in the bottom panel.

(C) Representative plots of normalized median GFP fluorescence intensity in endolysosomes (as marked by SiR-Lysosomes) over time (min) following dimerizer addition in control cells (*gray*) versus those overexpressing TQ-IFITM1 or 2 (*red*).


A




B




C




D



E




F



G

GFP-CD63	WCL	MVBs
Degradation + secretion	11%	18%
Degradation	5%	8%
Secretion	6%	10%

H



**Figure S4. Retrofusion and exosomes. Related to Figure 4.**

- (A) Electron micrographs of exosome isolates prepared as described in Figure 4F. Scale bar, 200 nm.
- (B) Biochemical profile of exosome isolates (secreted in absence of dimerizer) was assessed by immunoblot against the indicated markers. TfR: transferrin receptor, recycling endosomes; HLA-DR: MHC class II, LM and ILVs of late endosomes/lysosomes; Lamp2: LM of late endosomes/lysosomes; Golgin97: trans-Golgi network; Calnexin: endoplasmic reticulum; Tsg101: exosome marker. WCL: diluted whole-cell lysate (to prevent overloading control signal). The position of marker proteins is indicated.
- (C) Immunoblot analysis of GFP-CD63 (detected with anti-GFP antibodies) versus untagged CD63 in exosome isolates and a fraction of whole cell lysate (WCL) from control cells or cells overexpressing TQ-IFITM3 treated in the presence (+) or absence (-) of dimerizer. The different incubations as well as the position of the marker proteins are indicated.
- (D) Immunoblot analysis of CD63 in exosome isolates and WCL from control cells. Exosomes were isolated from  $10 \times 10^6$  cells. For the WCL,  $1.3 \times 10^6$  cells were loaded on the same gel. The results from a duplicate exosome isolation were loaded on two lanes as is the corresponding WCL. Position of marker proteins is indicated.
- (E) Quantification of GFP-CD63 signal in exosome isolates versus the signal in a fraction of WCL from control cells. Exosomes were isolated from  $10 \times 10^6$  cells and  $1.3 \times 10^6$  cells were loaded on the same gel. Shown is mean +/- SD from three independent experiments.
- (F) Quantification of the percentage of GFP-CD63 secreted in exosomes relative to the fraction cell lysate ( $1.3 \times 10^6$  cells) including MVBs. This is not corrected for the number of cells providing exosomes. The corrected values are shown in Figure 4H.